Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note issued to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $10.00 target price on the stock.

Several other analysts also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Monday, March 23rd. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Anixa Biosciences currently has an average rating of “Hold” and a consensus target price of $8.50.

Anixa Biosciences Price Performance

Shares of NASDAQ ANIX opened at $2.58 on Tuesday. Anixa Biosciences has a 1 year low of $2.33 and a 1 year high of $5.46. The stock has a market capitalization of $86.51 million, a P/E ratio of -7.82 and a beta of 0.48. The company’s 50-day moving average is $2.89 and its 200 day moving average is $3.53.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Research analysts anticipate that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insider Buying and Selling at Anixa Biosciences

In other Anixa Biosciences news, Director Arnold M. Baskies purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The stock was purchased at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the completion of the purchase, the director directly owned 135,000 shares of the company’s stock, valued at $410,400. This trade represents a 8.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 26.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Anixa Biosciences

Several institutional investors have recently modified their holdings of the business. NewEdge Advisors LLC bought a new stake in Anixa Biosciences in the 2nd quarter worth about $33,000. Northwestern Mutual Wealth Management Co. lifted its stake in Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after acquiring an additional 10,000 shares during the period. Cetera Investment Advisers purchased a new stake in shares of Anixa Biosciences during the 4th quarter valued at about $35,000. Benjamin Edwards Inc. purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at about $37,000. Finally, Marshall Wace LLP bought a new stake in shares of Anixa Biosciences in the second quarter worth approximately $39,000. 29.13% of the stock is owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.